REGN 3051
Alternative Names: REGN3051Latest Information Update: 28 Mar 2021
At a glance
- Originator Regeneron Pharmaceuticals
- Developer National Institute of Allergy and Infectious Diseases; Regeneron Pharmaceuticals
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Viral protein inhibitors; Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Middle East respiratory syndrome coronavirus
Most Recent Events
- 28 Mar 2021 No recent reports of development identified for phase-I development in Middle-East-respiratory-syndrome-coronavirus(In volunteers) in USA (IV, Infusion)
- 12 Feb 2018 Phase-I clinical trials in Middle East respiratory syndrome coronavirus (In volunteers) in USA (IV) (NCT03301090) (Regeneron pipeline, May 2018)